Home Remepy Reports Strong Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson’s Disease

Remepy Reports Strong Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson’s Disease

May 20, 2026 21:21 CST Updated 21:55